Fibromyalgia: What We Know, What We Don’t—and What Comes Next

A READER'S NET INVESTIGATION — INSPIRED BY A READER LIVING WITH FIBROMYALGIA

Fibromyalgia: What We Know, What We Don’t—and What Comes Next

A reader recently wrote to Founder’s Institute of Medicine & Education with a question millions of people with fibromyalgia have probably asked: What is actually causing this—and is medicine getting any closer to better answers?

She also shared something personal. She feels she has improved while following the guaifenesin protocol, an approach that has circulated in the fibromyalgia community for years. She gave us permission to use her experience anonymously.

That made her question perfect for Reader’s Net: listen to the person, respect the experience, then follow the evidence wherever it leads.

First: fibromyalgia is real

Fibromyalgia is characterized by widespread pain and commonly accompanied by fatigue and problems with sleep, mood, and memory. A 2026 clinical review in the New England Journal of Medicine describes the central nervous system in fibromyalgia as hyperresponsive to sensory stimuli. The condition can occur alone, overlap with other chronic pain syndromes, or occur alongside other diseases.

And the biology is becoming increasingly measurable.

A major Nature Medicine study published in July 2026 analyzed 2,563,755 people, including 54,629 fibromyalgia cases, and identified 26 genetic risk loci. Fibromyalgia heritability was enriched in brain tissue and neural cell types.

That does not mean there is now a simple “fibromyalgia gene test.” It means researchers are beginning to map biological architecture that was previously much harder to see.

So what may be happening?

Fibromyalgia is commonly discussed as a nociplastic pain condition. In plain language, pain processing can become altered so that the nervous system responds unusually strongly to sensory input.

But patients are not identical. Research continues into genetics, sleep, autonomic function, immune signaling, metabolism, the gut–brain axis, psychological factors, and other contributors. Some of these areas are established parts of the fibromyalgia picture; others remain active research questions.

What about the guaifenesin protocol?

Some patients report improvement while taking guaifenesin. Those experiences deserve to be heard. But an individual experience cannot by itself establish why improvement occurred or whether the same treatment will reliably help others.

The randomized placebo-controlled evidence has not established guaifenesin as an effective fibromyalgia treatment. A published JAMA review notes that the reported 12-month randomized trial found no significant effect on pain, other symptoms, or laboratory measures compared with placebo.

So we should not tell someone who feels better, “You didn’t really improve.” But we also should not say, “Your improvement proves the treatment works.”

Your experience is real. The scientific questions are why you improved, whether the effect can be reproduced, and whether the proposed mechanism is correct.

What can people do today?

There is no single universally effective fibromyalgia treatment. Current care is generally individualized and often combines non-drug and medication approaches. A 2026 review of therapeutic advances emphasizes a personalized, multidimensional approach and continued research into both pharmacologic and non-pharmacologic strategies.

What about genetics, stem cells, and regenerative medicine?

The new genetic findings are exciting because they may help researchers understand biological pathways, identify patient subgroups, and eventually uncover new therapeutic targets.

Stem-cell or gene-based therapy is not currently an established standard treatment for fibromyalgia. That does not close the door on future research. It simply keeps hope connected to evidence.

Could immune dysfunction be involved?

Possibly—but this remains an active research question rather than a settled conclusion. Researchers continue studying interactions among pain pathways, immune biology, metabolism, and other systems.

Want to look for a clinical trial yourself?

ClinicalTrials.gov, maintained by the U.S. National Library of Medicine, is the U.S. government database for registered clinical studies.

SEARCH FIBROMYALGIA STUDIES

Look at recruitment status, eligibility criteria, study locations, interventions, and contacts. A listing does not mean a study is appropriate for you. Discuss possible participation with your treating clinician and the study team.

The question behind the question

Why are people with the same diagnosis having such different experiences?

Perhaps fibromyalgia will remain one broad syndrome. Perhaps genetics, biomarkers, imaging, immune research, or other tools will eventually identify biologically meaningful subgroups. We do not know yet. But medicine now has better tools with which to ask the question.

To the reader who started this investigation

Thank you.

You asked us to look deeper. You allowed us to share your experience anonymously. And because you did, another person living with fibromyalgia may discover that medicine has not stopped looking for answers.

Your question made it onto Reader’s Net.

And we intend to keep watching the research.

— Milton Wright, DO, FACOFP
Founding Director
Founder’s Institute of Medicine & Education

Sources: New England Journal of Medicine: Fibromyalgia (2026) | Nature Medicine: genetic architecture of fibromyalgia (2026) | Therapeutic advances in fibromyalgia: one year in review 2026 | JAMA: Management of Fibromyalgia Syndrome | ClinicalTrials.gov: Fibromyalgia

This educational article is based on a de-identified reader question and is published with the reader’s consent. Educational information only; not individualized medical diagnosis or treatment advice.